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Abstract: Hypoxic areas in solid tumors are often associated with poor prognosis and resistance to chemothera-
py. The aim of the study was to analyze the expression of galectin-1 (Gal-1), galectin-3 (Gal-3), sialic acid and 
b1–6 branched glycan structures in hypoxic environment of invasive ductal carcinoma (IDC) of the breast. We 
performed lectin histochemistry with phytohemagglutinin-L (L-PHA) and Sambucus nigra lectin (SNA); and 
immunohistochemistry for Gal-1, Gal-3, carbonic anhydrase IX, hypoxia-inducible factor, estrogen receptor (ER), 
progesterone receptor and human epidermal growth factor receptor type-2 for 86 IDC samples. Patients with 
markers positive for hypoxia were mostly ER-negative (p = 0.003) and presented with more nodal invasion than 
the non-hypoxic group (p = 0.0439). Concerning the glycobiological aspects, the hypoxic group expressed more 
of Gal-3 (p = 0.0021) and SNA ligands (p = 0.0498), however, there was no association between lectin- and 
galectin-staining and clinical and histopathological data. Our results suggest a change in the glycomic profile of 
patients within hypoxic regions of IDC. However, further studies are needed to evaluate the role of lectin- and 
galectin-ligands in tumor’s hypoxic environment, as well as their potential to be used as therapeutic targets. 
(Folia Histochemica et Cytobiologica 2014, Vol. 52, No. 2, 96–103)
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Introduction
Breast cancer is the most common cancer among 
women, accounting for 22% of new cases every year, 
and the second most common cancer world wide [1]. 
Moreover, as with most solid tumors, breast can-
cers often have central regions of hypoxia which 
are usually peri-necrotic [2]. Cells that survive in 
this adverse environment are typically resistant to 
radiotherapy and chemotherapy and differ from 
cells in areas with adequate blood supply [3, 4]. 
Hypoxia-inducible factor 1a (HIF-1a) is the major 
modulator of hypoxic condition and is constitutively 
produced under low-oxygen conditions, which typi-
cally occurs at distances greater than 180 μm from 
blood vessel [5]. HIF-1a affects tumor progression 
and angiogenesis by modulating the expression of 
genes involved in the adaptation to oxygen- and 
nutrient-deficiency, leading to increased cell survival, 
inhibition of apoptosis and migration [6, 7]. Among 
these genes, carbonic anhydrase IX (CA IX) and 
glucose transporter 1 (GLUT1) play crucial roles in 
cellular adaptation, by altering the energy metabolism 
of neoplastic cells, which begin to show high rates of 
anaerobic glycolysis [2, 5–7]. The change in metabolic 
profile is followed by altered expression of enzymes 
involved in aerobic and anaerobic glycolysis, sugar 
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nucleotide transport and carbohydrate synthesis [8]. 
These modifications increase the amount of flux from 
the glycolytic pathway to the hexosamine pathway and 
the N-acetylglucosamine pathway, thereby altering 
key components of cellular glycosylation, such as 
substrates for glycosyltransferases [9].
Additionally, hypoxia influences the expression of 
molecules that change cellular behavior — one of these 
molecules is galectin 1 and galectin 3 (Gal-1 and Gal-3, 
respectively), a protein that appears to be pro-neoplastic 
in the hypoxic microenvironment [10, 11]. However, little 
is known about the glycomic aspects of breast cancer’s 
hypoxic environment and its possible implications. 
We therefore aimed to evaluate Gal-1 and Gal-3 
expression and the phytohemagglutinin-L (L-PHA) 
and SNA ligand profiles by immunohistochemical 
(IHC) and histochemical staining methods in the inva-
sive ductal carcinoma (IDC) of the breast within and 
beyond hypoxic areas of tumor tissue. We also evalu-
ated the possible correlations between the expression 
of these molecules and diagnostic and prognostic pa-
rameters and markers such as estrogen receptor (ER), 
progesterone receptor (PR) and human epidermal 
growth factor receptor type-2 (HER-2).
Material and methods
Sample collection. Eighty-six samples from IDC patients 
were selected from the Pathology Department at the Ho-
spital das Clinicas in the Federal University of Pernambuco, 
Brazil, (HC-UFPE) between 2002 and 2010. The tumor-free 
edges and 10 reductive mastoplasty biopsies were used as 
controls. Patients who had inflammatory or medullary car-
cinoma, or who were less than 30 years of age were excluded 
from the study. The Medical Records and Statistics Service 
of HC-UFPE provided the clinical and histopathological 
information about the patients. The clinicopathological 
data from patients included in the study is shown in Table 1. 
The study was approved by the human research ethics 
committee of the aforementioned institution (CEP/CCS/ 
/UFPE No 195/09).
Lectin histochemistry. Sections of IDC samples (4-mm 
thick) were deparaffinized in xylene and rehydrated in de-
creasing concentrations of ethanol. Sections were treated 
with trypsin, submitted to endogenous peroxidase blocking, 
and incubated with biotinylated SNA and L-PHA lectins 
at 20 mg/mL for 2 h at 25°C before incubation for 1 hour 
with streptavidin-peroxidase. L-PHA recognizes galectins’ 
ligands and SNA recognizes sialic acid that often mask those 
ligands. The excess reagent was removed in two baths of 
phosphate-buffered saline (PBS) for 5 min, the peroxidase 
color reaction was developed with diaminobenzidine-H2O2 
(DAB) and the nuclei were counter-stained with hema-
toxylin. Samples of ductal carcinoma in situ of the breast 
previously known to be positive for lectin histochemistry 
were used as positive controls, while the negative control 
was obtained by replacing the lectin with PBS and lectin 
inhibition with its specific sugar at a concentration of 300 
mM [12, 13]. All materials which source was not specified 
were obtained from SigmaAldrich (St. Louis, MO, USA).
Immunohistochemistry. Sections of IDC samples (4-mm 
thick) were deparaffinized in xylene and rehydrated in decre-
asing concentrations of ethanol. Antigen retrieval was per-
formed in citrate buffer (pH 6), at 95–99°C for 30 minutes, 
followed by treatment with endogenous peroxidase blocking 
solution (DAKO, Glostrup, Denmark) at room temperature 
for 15 min. Nonspecific sites were blocked with 1% PBS 
bovine serum albumin for 1 h at room temperature. Then 
sections were incubated with primary antibodies (Table 2) 
for 2 h at 37°C. The samples were incubated with biotin-free 
polymer (DAKO) and the peroxidase color reaction was 
developed by DAB-H2O2 (DAKO). Positive controls were 
performed as indicated by the antibody manufacturer; in the 
case of negative controls, the primary antibody was replaced 
with non-specific IgG (DAKO). 
Histological evaluation. For each sample, 10 fields were 
evaluated under the 40 × objective lens by two pathologists 
and only cells positive for neoplastic markers were counted. 
For the evaluation of hormone receptors, the scoring sys-
tem proposed by American Society of Clinical Oncology 
(ASCO) [15], which evaluates the proportion of stained 
nuclei and intensity of staining, was used. For the analysis 
of HER-2 we followed the criteria adopted by the ASCO 
and the College of American Pathologists Consensus [16], 
which considers the intensity of membrane staining and the 
percentage of stained cells. Reaction for CA IX was con-
sidered immunopositive when there was any indication of 
membrane staining, whereas HIF-1a expression was consi-
dered positive when there was nuclear staining in more than 
10% of the cancer cells analyzed [16]. Stainings for Gal-1, 
Gal-3, SNA and L-PHA were considered positive when at 
least 10% of cells showed cellular reactivity, irrespective of 
cellular location [12, 13, 17]. For the evaluation of stromal 
cells, 10 fields under the 40 × objective lens were evaluated 
and any positive stromal cells were included in the counting. 
The average number of positive stromal cells was compared 
between hypoxic and non-hypoxic (control) areas.
Statistical analysis. All statistical analyses were performed 
using GraphPad Prism software version 4.0 (GraphPad, La 
Jolla, CA, USA). Categorical data were assessed using the 
chi-square (c2) test. Differences were considered statistically 
significant at p < 0.05.
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Results
Hypoxic tumor samples are predominantly ER- 
-negative and associated with lymph node invasion
We first evaluated any clinical and histopathological 
differences between study groups. The 86 samples 
were subjected to HIF-1a  and CA IX immunohisto-
chemistry to confirm the presence of hypoxic areas. 
Samples of 20 patients presented neoplastic cells pos-
itive for hypoxic markers, showing nuclear staining for 
HIF-1a (Figure 1D) and membrane staining for CA IX 
(Figure 2A); these patients represented the hypoxic 
group. Conversely, samples of 66 patients were nega-
tive for hypoxic markers and they were considered the 
control group (non-hypoxic). Interestingly, the control 
group patients were of younger age (50.5 ± 5.2, mean 
and SD), whereas the hypoxic group had a higher mean 
age and standard deviation (58.6 ± 15.0), however, the 
difference was statistically not significant. We observed 
a direct association between the hypoxic group and 
nodal involvement (p = 0.0439). The other clinical 
and histopathological characteristics are summarized 
in Table 1.
Table 1. Clinical and histopathologic features of invasive ductal breast cancer (IDC) patients with hypoxic and  
non-hypoxic areas
Parameter Number and % 
 of IDC CA IX− cells  
(non-hypoxic group)
Number and %
of IDC CA IX+ cells  
(hypoxic group)
P value
Tumor size
    pT1 
    pT2 
    pT3 
    pT4 
 
20 (30.30%)
30 (45.50%)
4 (6.09%)
12 (18.20%)
 
2 (10%)
10 (50%)
6 (30%)
2 (10%)
 
> 0.05
Lymph node metastasis
    Yes 
    No
 
22 (33.33%)
44 (66.67%)
 
17 (65%)
3 (35%)
 
0.0439
Histological grade
    1 
    2 
    3 
 
15 (22.72%)
24 (36.36%)
27 (40.92%)
 
3 (15%)
5 (25%)
12 (60%)
 
> 0.05
Immunohistochemical markers
    ER+
    PR+
    HER-2+ 
 
22 (46.80%)
22 (46.80%)
3 (6.40%)
 
4 (20%)
13 (65%)
3 (15%)
 
0.0003
> 0.05
> 0.05
ER — estrogen receptor; PR — progesterone receptor; HER-2 — human epidermal receptor 2
Table 2. Sources of antibodies and lectins used for immunohistochemical and histochemical staining 
Primary antibody/lectin Source Dilution/concentration Clone
ER Santa Cruz Biotechnology, Dallas, TX, USA 1:100 1D5
PR Santa Cruz Biotechnology 1:150 1A6
HER-2 DAKO, Glostrup, Denmark 1:400 MIB1
GAL-3 Spring Bioscience, Pleasanton, CA, USA 1:150 9C4
M338 Hybridoma 1:20 –
GAL-1 Santa Cruz Biotechnology 1:100 C8
CA IX Santa Cruz Biotechnology 1:150 H-120
HIF-1a Santa Cruz Biotechnology 1:100 H-206
L-PHA Vector Labs, Burlingame, CA, USA 20 mg/ml –
SNA Vector Labs 20 mg/ml –
ER — estrogen receptor; PR — progesterone receptor; HER-2 — human epidermal receptor 2; Gal-3 — galectin-3; M338 — name given to the 
hybridoma producing anti-N-terminal Gal-3 antibody; Gal-1 — galectin-1; CA IX — carbonic anhydrase IX; HIF-1a — hypoxia-inducible factor 1; 
L-PHA — phytohemagglutinin-L; SNA — Sambucus nigra lectin
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In relation to markers predictive of treatment 
response (ER, PR and HER-2; Figure 1), we did not 
observe any significant difference between analyzed 
groups (p > 0.05). However, an inverse association 
between positive ER and CA IX immunoexpression 
in the hypoxic group was observed (p = 0.003). There 
were no significant correlations between CA IX and 
PR and HER-2 immunoreactivities in the hypoxia 
group (p > 0.05).
Increased expression of Gal-3 and SNA  
ligands in hypoxic samples of IDC
The glycomic analysis of analyzed samples revealed 
that SNA staining revealed more cases in the hypoxic 
group than in the control non-hypoxic group (p = 
0.0498), while there was no significant difference in 
L-PHA ligands between groups (p = 0.39) (Figure 2). 
There was no positive staining for Gal-1 in neoplastic 
cells of either of the two studied groups.
In an attempt to find possible associations between 
hypoxia, tumor histopathologic parameters and Gal-1 
immunoreactivity in stromal cells, cells positive for 
Gal-1 were counted in 10 randomly selected fields 
at the 40 × objective lens in the control and hypoxic 
samples. However, no differences were established 
(data not shown).
The immunohistochemical detection of Gal-3, was 
found in a higher number of cases in the hypoxic group 
compared with the non-hypoxic group (p = 0.0021), 
which was accompanied by a change in cytoplasmic 
and nuclear localization of Gal-3, with its increased 
nuclear localization in the hypoxic group (Figure 3B). 
Figure 2 summarizes the percentage of hypoxic and 
Figure 1. Immunohistochemical expression of markers used in the study of breast invasive ductal carcinoma. A. Her-2 
reveals intense membrane staining (arrow). Positive nuclear immunoreactivity for estrogen receptor (B, arrow), proge-
sterone receptor (C) and HIF-1a (D–E). The figure presents representative cases of the study. Magnification: A and E  
× 400; B, C and D × 100
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non-hypoxic IDC cases positive and negative for SNA, 
L-PHA and Gal-3 staining.
When we used M338 (antibody against N-terminal 
region of Gal-3), we found increased cytoplasmic 
staining with or without nuclear staining in the hy-
poxic group, however, the number of positive cases 
for this antibody was very low (data not shown). The 
subcellular localization analysis was also performed 
for SNA and L-PHA (Figure 3C and D, respectively). 
In the case of SNA, we noticed a marked tendency 
towards changing the cell staining pattern from the 
cytoplasmic and membranous, to the cytoplasmic 
only in the hypoxic group. The analysis of L-PHA 
subcellular staining did not show a significant change 
between hypoxic and nonhypoxic groups, only a small 
increase in cytoplasmic staining and a slight decrease 
in cytoplasm and membrane co-staining. 
Discussion
The tumor microenvironment consists of highly com-
plex cellular and molecular networks that contribute 
to the hallmarks of cancer, including evasion of cell 
death, self-sufficiency in secretion of growth signals, 
insensitivity to anti-proliferative signals, tissue inva-
sion and metastasis, limitless replicative potential, and 
angiogenesis [18]. These processes can be affected 
by hypoxia, which alters the expression of genes [2] in-
cluding those which encode galectin-1 and galectin-3, 
proteins which appear to modulate many of the 
tumor characteristics and play a key role in tumori-
genesis [19].
In the IDC samples, we observed that patients 
positive for CA IX had more aggressive clinical cha-
racteristics than previously reported [20]. CA IX is 
principally regulated at the transcriptional level and 
its expression is stimulated by hypoxia through HIF-1, 
which binds to the hypoxia responsive element (HRE) 
in the CA IX promoter to increase transcription [21]. 
Carbonic anhydrase IX confers an acidic micro-
environment compatible with tumor cell viability and 
proliferation and has been associated with necrosis, 
high tumor grade, higher relapse rates and worse ove-
rall survival in patients with breast carcinoma [22, 23].
Moreover, we found an inverse correlation at the 
level of IHC staining between ER and CA IX positi-
vity –– a fact that can be related to the predominant 
tumor subtype and menopausal status of patients 
with a possible poor prognosis. These data agree 
with previous results obtained by Tan et al. [24] and 
other authors [25–27]. Furthermore, CA IX expres-
sion in hypoxic regions is regarded as an indicator of 
resistance to chemotherapy and hormonal therapy, 
and may therefore be a target in hypoxia-specific 
therapies [28, 29].
The significant decrease in ER staining in the 
hypoxic group, which is associated with poor prog-
nosis [30], could relate to the fact that HIF-1a 
induces ER proteasomal degradation in hypoxic 
microenvironment, and decreases its transcription by 
reducing the RNApol II recruitment in the promoter 
region of ESR1 locus [31].
In the IDC samples, Gal-1 staining was observed 
in the tumor-associated stromal cells, but no signifi-
Figure 2. IDC percentage for the glycan markers, SNA, L-PHA, Gal-3 and M338 by study group. SNA lectin and anti-
Gal-3 were positive in a higher number of cases in the hypoxic group compared with the control non-hypoxic group.  
SNA — Sambucus nigra agglutinin; L-PHA — phytohemagglutinin lectin; M338 — name given to the hybridoma  
producing anti-N-terminal Gal-3; Gal-3 — galectin-3
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cant difference between the hypoxic and the control 
group was found. This is in contrast to glioblastoma, 
where neoplastic expression of Gal-1 is associated 
with clinical outcome and hypoxic regions [32]. One 
of the major roles of Gal-1 in cancer progression is 
immunosuppression, which facilitates a pro-tumori-
genic environment, thus, Gal-1 expression in stroma 
appears to be inversely proportional to the level of 
CD3 staining, i.e. presence of T lymphocytes [33, 34]. 
In head and neck cancers, the role of Gal-1 under 
hypoxic conditions represents a pivotal link between 
hypoxia and tumor-immune privilege [33]. However, 
one has to be careful with the interpretation of this 
data, because Gal-1 staining was found in parenchy-
mal and not stromal cells in the aforementioned study. 
Interestingly, in our study Gal-3 was significantly 
overexpressed in hypoxic IDC samples, with an incre-
ase in nuclear Gal-3 staining, which is associated with 
more aggressive tumors and worse prognosis [35]. On 
the other hand, decreased expression of cytoplasmatic 
Gal-3 is also associated with progression of human 
breast cancer [36, 37]. Furthermore, Gal-3 plays an 
important role in the regulation of Wnt/b-catenin 
signaling –– a key pathway in development, tissue 
homeostasis, and tumor growth [38].
In some specific environments, such as necrotic 
areas, Gal-3 and its ligands are overexpressed in 
glioblastoma in hypoxic regions known as pseudo-
palisades [39], as well as in regions around necrotic 
areas from ductal carcinoma in situ of the breast, as 
demonstrated in a previous study by our group [12]. 
Another interesting result was the low immunopositi-
vity of staining with M338 antibody which recognizes 
N-terminal region of Gal-3, a fact which could be 
Figure 3. Lectin- and antibody-staining in the hypoxic group of breast invasive ductal carcinoma. A. CA IX reactivity was 
present exclusively in cell membranes (N, necrotic core). B. Anti-gal-3 immunoreactivity intensely present in cytoplasm 
and nuclei (nuclear staining is highlighted in the inset). C. SNA immunopositive reaction in the cytoplasm is characteristic 
of O-glycosylation. D. L-PHA staining is present in cell membranes and cytoplasm. Abbreviations as for Table 2. Magnifi-
cation: A, B and D × 100; C × 200
~
~
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hypoxia: suppression of breast tumor growth and metasta-
relate to N-terminal cleavage performed by matrix 
metalloproteinases, as well as phosphorylation in 
hypoxic regions [40, 41].
Regarding glycomic markers, we found increased 
expression of SNA ligands in the hypoxic group. Since 
SNA recognizes sialic acid residues [42] the increased 
monosaccharides’ staining reflects their higher expres-
sion at the cell surface, which reduces interactions 
of tumor cells with the extracellular matrix, thereby 
facilitating metastasis and promoting immune-escape, 
associated with a poor prognosis in breast cancer [43]. 
Furthermore, L-PHA-negative cases were SNA-po-
sitive, suggesting that L-PHA might not recognize 
its ligand (branched b1,6 oligosaccharides) owing to 
steric impediment promoted by sialic acid; this was 
indeed the case in B-cell lymphomas, where L-PHA 
ligands were masked by sialic acid in an a2–6 link-
age [44] that is recognized by SNA.
To our knowledge this is the first report to analyze 
the glycomic profile in the hypoxic environment of 
breast cancer, and correlate data with diagnostic and 
prognostic markers. However, further studies are 
needed to evaluate the role of lectin- and galectin-li-
gands in tumor’s hypoxic environment, as well as their 
potential to be used as therapeutic targets.
Acknowledgments
We thank the Coordenaçao de Aperfeiçoamento 
de Pessoal de Nível Superior (CAPES), Fundaçao 
de Amparo a Ciencia e Tecnologia de Pernambuco 
(FACEPE) and Conselho Nacional de Desenvolvi-
mento Científico e Tecnológico (CNPq) for financial 
support and Carmelita Lima Bezerra Cavalcanti for 
technical support.
References
1. DeSantis C, Ma J, Bryan L et al. Breast cancer statistics, 2013. 
CA Cancer J Clin. 2014;64:52–62.
2. Ruan K, Song G, Ouyang G. Role of hypoxia in the hall- 
marks of human cancer. J Cell Biochem. 2009;107:1053–1062. 
3. Moeller B, J Richardson RA, Dewhirst MW. Hypoxia and 
radiotherapy: opportunities for improved outcomes in cancer 
treatment. Cancer Metastasis Rev. 2007;26:241–248.
4. Cosse JP, Michiels C. Tumour hypoxia affects the responsi-
veness of cancer cells to chemotherapy and promotes cancer 
progression. Anticancer Agents Med Chem. 2008;8:790–797.
5. Adams JM, Difazio LT, Rolandelli RH et al. HIF-1: a key 
mediator in hypoxia. Acta Physiol Hung. 2009;96:19–28. 
6. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev 
Cancer. 2003;310:721–732. 
7. Powis G, Kirkpatrick L. Hypoxia inducible factor-1alpha as 
a cancer drug target. Mol Cancer Ther. 2004;3:647–654.
8. Shirato K, Nakajima K, Korekane H et al. Hypoxic regulation 
of glycosylation via the N-acetylglucosamine cycle. J Clin 
Biochem Nutr. 2008;48:20–25. 
9. Taniguchi N. From the gamma-glutamyl cycle to the glycan 
cycle: a road with many turns and pleasant surprises. J Biol 
Chem. 2009;11:34469–34478. 
~
~
103The influence of hypoxia on the tumor glycomic profile
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2014
10.5603/FHC.2014.0017
www.fhc.viamedica.pl
č
sis by novel carbonic anhydrase IX inhibitors. Cancer Rev. 
2011;171:3364–3376.
30. Agurs-Collins T, Dunn BK, Browne D et al. Epidemiology of 
health disparities in relation to the biology of estrogen recep-
tor-negative breast cancer. Semin Oncol. 2010;37:384–401.
31. Ryu K, Park C, Joo-lee Y. Hypoxia-inducible factor 1 alpha 
represses the transcription of the estrogen receptor alpha gene 
in human breast cancer cells. Biochem Biophys Res Commun. 
2011;407:831–836. 
32. Jung TY, Jung S, Ryu, HH et al. Role of galectin-1 in mi-
gration and invasion of human glioblastoma multiforme cell 
lines. J Neurosurg. 2008;109:273–284. 
33. Le QT, Shi G, Cao H et al. Galectin-1: a link between 
tumor hypoxia and tumor immune privilege. J Clin Oncol. 
2005;23:8932–8941.
34. Ito K, Stannard K, Gabutero E. Galectin-1 as a potent target 
for cancer therapy: role in the tumor microenvironment. 
Cancer Metastasis Rev. 2012;31:763–778. 
35. Moisa A, Fritz P, Eck A. Growth/adhesion-regulatory tissue 
lectin galectin-3: stromal presence but not cytoplasmic/nuclear 
expression in tumor cells as a negative prognostic factor in 
breast cancer. Anticancer Res. 2007;27:2131–2139.
36. Castronovo V, Van Den Brule FA, Jackers P. Decreased 
expression of galectin-3 is associated with progression of 
human breast cancer. J Pathol. 1996;179:43–48. 
37. Shekhar MP, Nangia-Makker P, Tait L et al. Alterations 
in galectin-3 expression and distribution correlate with 
breast cancer progression: functional analysis of galectin-3 
in breast epithelial-endothelial interactions. Am J Pathol. 
2004;165:1931–1941. 
38. Song S, Mazurek N, Liu C et al. Galectin-3 mediates nuclear 
beta-catenin accumulation and Wnt signaling in human colon 
cancer cells by regulation of glycogen synthase kinase-3beta 
activity. Cancer Res. 2009;69:1343–1349.
39. Ikemori RY, Machado CML, Nonogaki S, Verinaud L, 
Chammas R. Hypoxia-induced galectin-3 plays a role in the 
survival of nutrient deprived glioblastoma cells. In: Annual 
Meeting of the Society for Glycobiology, 2009, San Diego. 
Glycobiology (Oxford), 2009;19:1318. Available at: http://
glycob.oxfordjournals.org/content/19/11/1259.full.pdf+html.
40. Balan V, Nangia-makker P, Jung YS et al. Galectin-3: 
A novel substrate for c-Abl kinase. Biochim Biophys Acta. 
2010;1803:1198–1205. 
41. Ochieng J, Green B, Evans S et al. Modulation of the bio-
logical functions of galectin-3 by matrix metalloproteinases. 
Biochim Biophys Acta. 1998;1379:97–106.
42. Wang Y, Ao X, Vuong H. Membrane glycoproteins associated 
with breast tumor cell progression identified by a lectin affinity 
approach. J Proteome Res. 2008;10:4313–4325.
43. Chi-long C, Chu J, Su W et al. Hypoxia and metabolic phe-
notypes during breast carcinogenesis: expression of HIF-1a, 
GLUT1, and CAIX. Virchows Arch. 2010;457:53–61. 
44. Suzuki O, Nozawa Y, Kawaguchi T et al. Alpha-2,6-sialyla-
tion of L-PHA reactive oligosaccharides and expression of 
N-acetylglucosaminyltransferase V in human diffuse large B 
cell lymphoma. Oncol Rep. 2003;10:1759–1764.
Submitted: 4 March, 2014 
Accepted after reviews: 22 June, 2014
